<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391014</url>
  </required_header>
  <id_info>
    <org_study_id>2005-000703-34</org_study_id>
    <secondary_id>AMBINEB</secondary_id>
    <nct_id>NCT00391014</nct_id>
  </id_info>
  <brief_title>Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis</brief_title>
  <acronym>AMBINEB</acronym>
  <official_title>AMBINEB: Clinical Trial to Evaluate Tolerance and Safety of Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis in Patients With Acute Myeloid Leukemia and Allogeneic Haematopoietic Progenitor Cell Transplant (Alo-HPCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is planned as a multicentric, national, phase II, open-label trial to evaluate
      safety and tolerance of nebulized Liposomal Amphotericin B (Ambisome) for LMA patients during
      the induction therapy ,intensification, plus Allogeneic Haematopoietic Progenitor Cell
      transplant in due course, as well for patients diagnosed of several malignant haematologic
      diseases and treated with Allogeneic Haematopoietic Progenitor Cell Transplant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The invasive fungal infection (IFI) is the most common cause of mortality related to
      autologous stem cell transplant. Taking into account that Saprophytic Aspergillus is usually
      acquired by inhalation, to protect the bronchial tree just before the tissue invasion is
      quite attractive. In haematologic patients, as well as those ones subjected to an Allogeneic
      haematopoietic progenitor cell transplant, there is another group of patients at high risk of
      Invasive Pulmonary Aspergillosis (IPA). These are those patients with acute myeloid leucemia
      (AML), submitted to induction, intensification or consolidation polychemotherapy. The IPA
      incidence rate in these patients, whenever during their evolution, reaches 18-20%, with usual
      treatments. Furthermore, unlike allogeneic haematopoietic progenitor cell transplant
      patients, neutropenia was the only IPA risk factor. Nowadays, pharmacologic prophylaxis
      against IPA, in patients with allogeneic haematopoietic progenitor cell transplant and
      patients affected by AML in induction or intensification therapy is far from being optimal,
      because of problems related to tolerance and drug interactions .

      The Nebulized Liposomal Amphotericin B (Ambisome) prophylaxis against IPA has shown good
      tolerance, safety and efficacy in lung transplant recipients.

      Extrapolating the results obtained in lung transplant recipients, we get the conclusion that
      it would be essential to study safety and tolerance of nebulized AMBISOME in the group of
      patients with different peculiarities, mucositis secondary to chemotherapy, and high
      incidence of IPA in order to reach the goal of evaluate its efficacy as prophylaxis against
      IPA in this kind of patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and safety prophylaxis against IPA in LMA patients.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Allogeneic Haematopoietic Progenitor Cell Transplant</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.
If patient required ALO-TPH, the prophylaxis should be followed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal Amphotericine B</intervention_name>
    <description>AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.
If patient required ALO-TPH, the prophylaxis should be followed.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has decided voluntary to consent his or her participation signing the consent
             form before performance of any study-related procedure not part of normal medical
             care, with the understanding that consent may be withdrawn by the patient at any time
             without prejudice to their future medical care.

          -  Patients with Acute myeloid Leukemia (AML), that will start induction chemotherapy or
             those patients submitted to an Allogeneic haematopoietic progenitor cell transplant.

          -  The patient is &gt;18 years old.

        Exclusion Criteria:

          -  Patient with prior Invasive Pulmonary Aspergillosis (IPA) history.

          -  History of allergy or hypersensitivity to Amphotericin B.

          -  Patient with intellectual deficit or patients with psychological alterations that make
             impossible the trial understanding.

          -  Pregnancy or breastfeeding.

          -  Patient has received other investigational drug or non traded product within 30 days
             before trial beginning.

          -  Patient is enrolled in another clinical research study or/and is receiving an
             investigational agent for any reason.

          -  Patient had major surgery within 4 weeks before enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruiz Isabel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rovira Montserrat, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.aehh.org</url>
    <description>Spanish association of Haematology</description>
  </link>
  <reference>
    <citation>Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5. Review.</citation>
    <PMID>9564455</PMID>
  </reference>
  <reference>
    <citation>Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002 Dec 15;100(13):4358-66. Epub 2002 Aug 22.</citation>
    <PMID>12393425</PMID>
  </reference>
  <reference>
    <citation>Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003 May 6;138(9):705-13.</citation>
    <PMID>12729424</PMID>
  </reference>
  <reference>
    <citation>Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL, Diekema DJ, Pfaller MA. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004 Aug 15;39(4):584-7. Epub 2004 Jul 30.</citation>
    <PMID>15356827</PMID>
  </reference>
  <reference>
    <citation>Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ, Stevens DA, Theodore J. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):552-6.</citation>
    <PMID>1654038</PMID>
  </reference>
  <reference>
    <citation>Yeldandi V, Laghi F, McCabe MA, Larson R, O'Keefe P, Husain A, Montoya A, Garrity ER Jr. Aspergillus and lung transplantation. J Heart Lung Transplant. 1995 Sep-Oct;14(5):883-90.</citation>
    <PMID>8800724</PMID>
  </reference>
  <reference>
    <citation>Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996 Mar 27;61(6):915-9.</citation>
    <PMID>8623160</PMID>
  </reference>
  <reference>
    <citation>Cahill BC, Hibbs JR, Savik K, Juni BA, Dosland BM, Edin-Stibbe C, Hertz MI. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997 Nov 5;112(5):1160-4.</citation>
    <PMID>9367451</PMID>
  </reference>
  <reference>
    <citation>Reichenspurner H, Gamberg P, Nitschke M, Valantine H, Hunt S, Oyer PE, Reitz BA. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc. 1997 Feb-Mar;29(1-2):627-8.</citation>
    <PMID>9123449</PMID>
  </reference>
  <reference>
    <citation>Calvo V, Borro JM, Morales P, Morcillo A, Vicente R, Tarrazona V, París F. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest. 1999 May;115(5):1301-4.</citation>
    <PMID>10334143</PMID>
  </reference>
  <reference>
    <citation>Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest. 1995 Sep;108(3):750-3.</citation>
    <PMID>7656628</PMID>
  </reference>
  <reference>
    <citation>Schmitt HJ, Bernard EM, Häuser M, Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1988 Nov;32(11):1676-9.</citation>
    <PMID>3252750</PMID>
  </reference>
  <reference>
    <citation>Monforte V, Roman A, Gavalda J, Bravo C, Tenorio L, Ferrer A, Maestre J, Morell F. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant. 2001 Dec;20(12):1274-81.</citation>
    <PMID>11744410</PMID>
  </reference>
  <reference>
    <citation>Monforte V, Roman A, Gavaldá J, López R, Pou L, Simó M, Aguadé S, Soriano B, Bravo C, Morell F. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation. 2003 May 15;75(9):1571-4.</citation>
    <PMID>12792517</PMID>
  </reference>
  <reference>
    <citation>Lambros MP, Bourne DW, Abbas SA, Johnson DL. Disposition of aerosolized liposomal amphotericin B. J Pharm Sci. 1997 Sep;86(9):1066-9.</citation>
    <PMID>9294824</PMID>
  </reference>
  <reference>
    <citation>Thomas DA, Myers MA, Wichert B, Schreier H, Gonzalez-Rothi RJ. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest. 1991 May;99(5):1268-70.</citation>
    <PMID>2019191</PMID>
  </reference>
  <reference>
    <citation>Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int. 2003 Nov;53(11):744-50.</citation>
    <PMID>14629297</PMID>
  </reference>
  <reference>
    <citation>Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, Muti G, Marbello L, Tedeschi A, Magliano E, Morra E. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol. 2001 Dec;68(4):231-6.</citation>
    <PMID>11754411</PMID>
  </reference>
  <reference>
    <citation>Behre GF, Schwartz S, Lenz K, Ludwig WD, Wandt H, Schilling E, Heinemann V, Link H, Trittin A, Boenisch O, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol. 1995 Dec;71(6):287-91.</citation>
    <PMID>8534760</PMID>
  </reference>
  <reference>
    <citation>Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, Trittin A, Kern WV, Boenisch O, Bosse D, Lenz K, Ludwig WD, Hiddemann W, Siegert W, Beyer J. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999 Jun 1;93(11):3654-61.</citation>
    <PMID>10339471</PMID>
  </reference>
  <reference>
    <citation>Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 1990 Jun;5(6):403-6.</citation>
    <PMID>2196098</PMID>
  </reference>
  <reference>
    <citation>Myers SE, Devine SM, Topper RL, Ondrey M, Chandler C, O'Toole K, Williams SF, Larson RA, Geller RB. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma. 1992 Oct;8(3):229-33.</citation>
    <PMID>1490149</PMID>
  </reference>
  <reference>
    <citation>Erjavec Z, Woolthuis GM, de Vries-Hospers HG, Sluiter WJ, Daenen SM, de Pauw B, Halie MR. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis. 1997 May;16(5):364-8.</citation>
    <PMID>9228476</PMID>
  </reference>
  <reference>
    <citation>Hertenstein B, Kern WV, Schmeiser T, Stefanic M, Bunjes D, Wiesneth M, Novotny J, Heimpel H, Arnold R. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol. 1994 Jan;68(1):21-6.</citation>
    <PMID>8110874</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2006</study_first_submitted>
  <study_first_submitted_qc>October 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2006</study_first_posted>
  <last_update_submitted>May 11, 2009</last_update_submitted>
  <last_update_submitted_qc>May 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pethema</name_title>
    <organization>pethema</organization>
  </responsible_party>
  <keyword>Acute myeloid Leukemia</keyword>
  <keyword>Allogeneic haematopoietic progenitor cell transplant</keyword>
  <keyword>Acute Invasive Aspergillosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

